Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin Watts, Michael Maris, Tara L. Lin, Prapti Patel, Yazan F. Madanat, Christopher R. Cogle, Gautam Borthakur, Dirk Huebner, Noor Khaskhely, Lynn Bonham, Monica Massaro, Daphne Taylor, Caroline Taromino, Alice S. Mims

Blood (2022) 140 (Supplement 1): 6204–6205.

https://doi.org/10.1182/blood-2022-167468

Published: 2022

Journal Articles

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Michel Delforge, MDPhD, Rachid C. Baz, MD, Michele Cavo, Natalie S. Callander, MD, Armin Ghobadi, MD, Paula Rodriguez-Otero, MD PhD, María-Victoria Mateos, MD PhD, Monica Massaro, MPH, Li Ding, Payal Patel, Gianfranco Pittari, MD PhD, Steven Novick, MDPhD, Sergio A. Giralt, MD, Jesus G. Berdeja, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137156

Published: 2020

Journal Articles

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142426

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Nina Shah, MD, Melissa Alsina, MD, David S Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L Kaufman, MD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Kristen Hege, MD, Fabio Petrocca, MD, Jesus G. Berdeja, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 488.

https://doi.org/10.1182/blood-2018-99-116953

Published: 2018

NARROW

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Email alerts

ASH Publications

American Society of Hematology

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only